
Benitec Biopharma BNTC
$ 9.31
-5.39%
Benitec Biopharma EV/EBITDA Ratio | BNTC
Annual EV/EBITDA Ratio Benitec Biopharma
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -7.59 | -9.44 | -34.9 | -0.31 | 0.0351 | 0.734 | 0.271 | -2.67 | -2.11 | -1.38 | 0.109 | -7.47 | -0.699 | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 0.734 | -34.9 | -5.03 |
EV/EBITDA Ratio of other stocks in the Biotechnology industry
| Issuer | EV/EBITDA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
BioXcel Therapeutics
BTAI
|
-2.54 | $ 0.07 | 9.81 % | $ 855 K | ||
|
InflaRx N.V.
IFRX
|
-1.93 | $ 1.21 | -7.63 % | $ 81.4 M | ||
|
XTL Biopharmaceuticals Ltd.
XTLB
|
-396 | $ 1.78 | 16.33 % | $ 1.2 B | ||
|
22nd Century Group
XXII
|
-0.173 | $ 1.46 | -10.43 % | $ 269 K | ||
|
Ironwood Pharmaceuticals
IRWD
|
-1.16 | $ 4.82 | 2.99 % | $ 780 M | ||
|
Jazz Pharmaceuticals plc
JAZZ
|
-23.5 | $ 245.39 | 0.76 % | $ 15 B | ||
|
Zai Lab Limited
ZLAB
|
-99.8 | $ 26.56 | -1.12 % | $ 29.1 B | ||
|
Zentalis Pharmaceuticals
ZNTL
|
-1.5 | $ 1.8 | 3.16 % | $ 129 M | ||
|
CohBar
CWBR
|
-0.0334 | - | -15.44 % | $ 2.2 M | ||
|
Zoetis
ZTS
|
135 | $ 82.45 | 0.15 % | $ 36.6 B | ||
|
NeuBase Therapeutics
NBSE
|
0.988 | - | -1.56 % | $ 12.3 M | ||
|
Deciphera Pharmaceuticals
DCPH
|
-5.93 | - | - | $ 2.18 B | ||
|
Arena Pharmaceuticals
ARNA
|
-8.74 | - | -6.81 % | $ 3.04 B | ||
|
Scopus BioPharma
SCPS
|
-0.314 | - | -48.37 % | $ 3.71 M | ||
|
Annovis Bio
ANVS
|
-1.23 | $ 0.85 | -5.53 % | $ 17.5 M | ||
|
scPharmaceuticals
SCPH
|
-0.286 | - | - | $ 218 M | ||
|
Johnson & Johnson
JNJ
|
13.1 | $ 281.13 | -0.35 % | $ 677 B | ||
|
Kala Pharmaceuticals
KALA
|
0.0884 | $ 0.17 | -2.59 % | $ 1.39 M | ||
|
Entasis Therapeutics Holdings
ETTX
|
-0.978 | - | - | $ 105 M | ||
|
Athersys
ATHX
|
0.12 | - | 3.77 % | $ 22.4 M | ||
|
Global Blood Therapeutics
GBT
|
-6.65 | - | - | $ 4.62 B | ||
|
Longeveron
LGVN
|
-750 | $ 2.77 | 37.81 % | $ 48.7 B | ||
|
Inozyme Pharma
INZY
|
-0.428 | - | - | $ 207 M | ||
|
MediWound Ltd.
MDWD
|
-13.1 | $ 14.05 | -0.21 % | $ 382 M | ||
|
Idera Pharmaceuticals
IDRA
|
-1.86 | - | -23.04 % | $ 26.6 M | ||
|
Mirum Pharmaceuticals
MIRM
|
2.69 K | $ 94.4 | 1.31 % | $ 4.74 B | ||
|
NanoString Technologies
NSTG
|
-4.54 | - | -37.43 % | $ 5.1 M | ||
|
Humanigen
HGEN
|
-0.883 | - | -81.12 % | $ 4.28 M | ||
|
Sorrento Therapeutics
SRNE
|
-0.959 | - | -29.58 % | $ 126 M | ||
|
Surface Oncology
SURF
|
-0.931 | - | - | $ 59.7 M | ||
|
Sierra Oncology
SRRA
|
-2.09 | - | -0.05 % | $ 1.34 B | ||
|
Cocrystal Pharma
COCP
|
-0.867 | $ 1.03 | -6.33 % | $ 11.6 M | ||
|
Atea Pharmaceuticals
AVIR
|
-2.05 | $ 4.24 | -3.97 % | $ 346 M | ||
|
Nektar Therapeutics
NKTR
|
-9.13 | $ 37.82 | -0.01 % | $ 638 M | ||
|
Vaccinex
VCNX
|
-0.372 | - | -61.37 % | $ 654 K | ||
|
Nymox Pharmaceutical Corporation
NYMX
|
-6.09 | - | -19.68 % | $ 18.4 M | ||
|
Akero Therapeutics
AKRO
|
-10.5 | - | - | $ 3.67 B | ||
|
Lineage Cell Therapeutics
LCTX
|
-12.5 | $ 1.05 | -3.24 % | $ 242 M | ||
|
Jounce Therapeutics
JNCE
|
1.47 | - | - | $ 98.4 M | ||
|
Verona Pharma plc
VRNA
|
-285 | - | - | $ 69.7 B | ||
|
Corner Growth Acquisition Corp.
COOL
|
-55 | - | -0.89 % | $ 114 M | ||
|
Acorda Therapeutics
ACOR
|
0.0567 | - | -24.86 % | $ 820 K | ||
|
Ampio Pharmaceuticals
AMPE
|
-8.6 | - | -11.43 % | $ 502 K | ||
|
Akari Therapeutics, Plc
AKTX
|
-469 | $ 7.0 | -8.62 % | $ 471 B | ||
|
Mersana Therapeutics
MRSN
|
65.4 | - | - | $ 3.56 B | ||
|
CymaBay Therapeutics
CBAY
|
-33.3 | - | - | $ 3.45 B | ||
|
Freeline Therapeutics Holdings plc
FRLN
|
-2.56 | - | - | $ 384 M | ||
|
Genmab A/S
GMAB
|
2.7 | $ 54.08 | -3.08 % | $ 3.5 B | ||
|
Allakos
ALLK
|
-0.000271 | - | - | $ 28.6 M | ||
|
Timber Pharmaceuticals
TMBR
|
-0.0202 | - | - | $ 717 K |